Cardiovascular News - latest articles on cardiology treatment & research

Audio and Video interviews, recorded on-site at major, international conferences. InCirculation.net Editorial Board members discuss the major clinical trials with Key Opinion Leaders. Listen or view on-line or download for your mobile device.

Filter Expert Interviews using:

AVERROES

Desmond Julian and Freek Verheugt discuss the fascinating results of this trial, which was halted early owing to the significant benefit of apixaban versus aspirin in reducing the risk of stroke.

News Report Single-Slide Summary

ANTIPAF

John Camm and Bernard Gersh review this trial, which analyzed the efficacy and safety of angiotensin II-antagonist in the treatment of patients with paroxysmal atrial fibrillation.

News Report Single-Slide Summary

DANPACE

John Camm and Bernard Gersh discuss the confusing results of this widely criticised trial.

News Report Single-Slide Summary

ATOLL and ISAR REACT 3A

Harvey White joins Christian Hamm to review the ATOLL and ISAR REACT 3A trials and to discuss the case for and against unfractionated heparin.

ATOLL News Report
ATOLL Single-Slide Summary

ISAR REACT 3A News Report
ISAR REACT 3A Single-Slide Summary

ART

Roger Hall and Pieter Kappetein review the 1-year data from the ART trial, comparing bilateral versus single internal mammary grafting.

News Report Single-Slide Summary

SHIFT

Barry Massie interviews Inder Anand about the SHIFT trial, which showed that ivabradine significantly reduced the risk of heart failure.

News Report Single-Slide Summary

ALPHA OMEGA

Desmond Julian and Daan Kromhout agree: there's more to fatty fish than just fat.

News Report Single-Slide Summary

PEARL HF

Henry Dargie gives John McMurray his thoughts on the PEARL HF trial, which evaluated whether the potassium-sparing RLY5016 can reduce hyperkalemia in heart failure patients receiving spironolactone therapy.

News Report Single-Slide Summary

ACTIVE

The ACTIVE trial did not meet its primary endpoint and will not change our management of patients with atrial fibrillation, but it confirms the usefulness of ARBs in patients with various cardiac conditions. Leif Erhardt asks John McMurray for his thoughts.

MADIT-CRT

Günter Breithardt gives Bernard Gersh his thoughts about the MADIT-CRT trial, which showed that cardiac resynchronisation therapy can delay disease progression in HF class I or II patients.

New risk factors in MI

In this fascinating interview, Valentin Fuster reveals his ideas for promising new approaches to identify risk factors for potential myocardial infarction patients.

NORDISTEMI

Freek Verheugt and Bernard Gersh agree that the results of NORDISTEMI advocate a strategy of 'drip and ship' for thrombolysis-treated STEMI patients with very long transfer times to PCI hospitals.

JUPITER

'We should not deprive the elderly patients of the benefits of statins,' says Gabriel Steg, during his discussion with Bernard Gersh on the JUPITER sub-study.

PLATO

Roger Hall and Freek Verheugt discuss the PLATO trial, which has revealed that the oral anti-platelet drug tigagrelor significantly reduces the rate of MI, stroke and cardiovascular death in comparison with clopidogrel-aspirin combination in patients with acute coronary syndrome.

RE-LY

Leif Erhardt and John Camm discuss RE-LY and ponder whether the trial heralds a paradigm shift in the antithrombotic management of atrial fibrillation.

AAA

Desmond Julian interviews Carlo Patrono about the AAA trial, a study into the use of low-dose aspirin in the prevention of cardiovascular events and death in subjects with asymptomatic atherosclerosis.